Table 4.
Study using chemotherapy and radiation therapy for CAS.
| Study | N | Patients tumor location/size | Treatment | RT dose | Response/pattern of failure | Median OS (months) |
|---|---|---|---|---|---|---|
| Mark et al. (47) | 5 | Scalp: 4 and Face: 1 Size not described |
Anthracyclines | 30–76.2 Gy | Response ratio: N.D. Local: 2/5 Distant: 2/5 |
27.0 |
| 4 | Scalp: 1 and Face: 3 Size not described |
Surgery | 50–65 Gy | Local: 1/4 Distant: 0/4 |
Not reached | |
| Rhomberg et al. (99) | 1 | Scalp/face: 1 T2 |
Razoxane Vindesine |
35–66 Gy | CR Alive without failure |
41 |
| Miki et al. (98) | 11 |
Scalp: 16 and Face: 1 T1: 1 and T2: 15 |
Docetaxel |
70 Gy | Response ratio: 82% Local: 4 Distant: 5 Both: 4 |
 |
| 5 | Surgery/IL-2 | |||||
| Our study (19) | 16 | Scalp: 14, and Extremity: 2 T1: 2 and T2: 14 |
Docetaxel | <65Gy:12 ≧65Gy:16 |
 |
|
| 12 | Scalp: 10, extremity: 2 T1: 2 and T2: 10 |
Surgery | ||||
*P < 0.05.
**P < 0.01.
OS, overall survival; CAS, cutaneous angiosarcoma; N.D., not described; IL-2: interleukin-2.